Orexo said the FDA's request for additional technical data was unexpected, and added that it will work with the agency to enable a resubmission of the drug's marketing application.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/xVq3cZi
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment